TG Therapeutics | TGTX - Operating Expenses


TG Therapeutics reported $142.08M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alaunos Therapeutics USD 1.19M 148K Sep/2025
Amgen USD 5.9B 773M Dec/2025
Ardelyx USD 120.12M 14.46M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Bayer EUR 10.33B 126M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
Corcept Therapeutics USD 197.64M 219K Dec/2025
Curis USD 9.02M 23.01M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
J&J USD 17.44B 1.53B Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Novavax USD 126.2M 23.62M Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Verastem USD 59.01M 21.98M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025